Keros Therapeutics CFO Keith Regnante resigns, interim replacement named

Keros Therapeutics disclosed in a Form 8-K dated July 17, 2026 that Keith Regnante resigned from his role as Chief Financial Officer of the company, effective August 3, 2026, to pursue other opportunities.¹ The company said Regnante's resignation was voluntary and was not the result of any disagreement with the company on any matter relating to accounting practices, financial statements, internal controls over financial reporting, operations, policies or practices.¹ Keros added that it has commenced a search for a new Chief Financial Officer.¹

To fill the gap, the company's Board of Directors appointed Annita Tanini, the company's Corporate Controller and Vice President, Finance, as interim principal financial officer and principal accounting officer, effective as of August 4, 2026.¹ Tanini, age 55, has served in finance leadership roles at the company since May 2019, most recently as Corporate Controller and Vice President, Finance.¹ Her earlier career included serving as Vice President of Finance at Avedro, Inc., a commercial-stage ophthalmic medical technology company, from December 2015 to April 2017, and as Senior Vice President of Finance at Fiksu, Inc., a mobile advertising and marketing technology company, from March 2014 to November 2015.¹

Under her new employment agreement effective August 4, 2026, Tanini will receive an annual base salary of $302,300 and will be eligible for an annual cash bonus with a target amount equal to 30% of her annual base salary.¹ If terminated without cause or if she resigns for good reason, Tanini would be eligible for six months of her then-current base salary paid in installments, plus company payment of COBRA premiums for her and eligible dependents for up to six months, subject to a signed release of claims.¹

Regarding Regnante's departure, the filing states he is entitled to accrued base salary through the separation date, reimbursement of outstanding business expenses, and the right to elect COBRA continuation coverage at his own expense, but is not entitled to any additional severance payments, compensation or benefits except as required by applicable law.¹